The Road to a Malaria-Free World: The Promise of R21/Matrix-M Vaccine

Abstract

Get full access to this article

View all access options for this article.

References

Aderinto

Olatunji

Kokori

Sikirullahi

Aboje

Ojabo

RE.

A perspective on Oxford’s R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. Malar J. 2024;23(1):16. doi:10.1186/s12936-024-04846-w

Datoo

Natama

Somé

, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet (London, England). 2021;397(10287):1809-1818.

Datoo

Dicko

Tinto

, et al. R21/Matrix-M Phase 3 Trial Group. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403(10426):533–544. doi: 10.1016/S0140-6736(23)02511-4.

University of Oxford. R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana. Accessed February 8, 2024. https://www.ox.ac.uk/news/2023-04-13-r21matrix-m-malaria-vaccine-developed-university-oxford-receives-regulatory

RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31-45.